Skip to main content
Print Save

Synjardy FDA Approval History

FDA Approved: Yes (First approved August 26, 2015)
Brand name: Synjardy
Generic name: empagliflozin and metformin
Dosage form: Tablets
Company: Eli Lilly and Company and Boehringer Ingelheim
Treatment for: Diabetes, Type 2

Synjardy (empagliflozin and metformin hydrochloride) is a sodium glucose co-transporter-2 (SGLT2) inhibitor and biguanide combination for the treatment of adults with type 2 diabetes.

Development timeline for Synjardy

DateArticle
Dec 12, 2016Approval FDA Approves Synjardy XR (empagliflozin/metformin hydrochloride extended-release) for Adults with Type 2 Diabetes
Jul 19, 2016Approval FDA Expands Indication For Type 2 Diabetes Treatment Synjardy (Empagliflozin/Metformin Hydrochloride) To Include Treatment-Naïve Adults
Aug 27, 2015Approval FDA Approves Synjardy (empagliflozin/metformin hydrochloride) for Type 2 Diabetes
Oct 21, 2014U.S. FDA Accepts Filing Of NDA for Empagliflozin/Metformin Fixed-Dose Combination

See also

Synjardy (empagliflozin and metformin) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer